Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop
February 24 2014 - 10:00AM
Galectin Therapeutics Inc. (Nasdaq:GALT), the
leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today announced that the Company will
present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted
by JMP Securities on Thursday, February 27, 2014 in New York, NY.
NASH, a progressive liver disease caused by the accumulation of fat
in the liver leading to inflammation and fibrosis, is estimated to
affect nine to 15 million people, including children, in the United
States.
Peter G. Traber, M.D., Chief Executive Officer, President and
Chief Medical Officer of Galectin Therapeutics, will serve on the
NASH diagnostic and therapeutics panel, to be held at Aquavit
Restaurant (66 E. 55th Street) from 7:30 a.m. to 11:30 a.m. Eastern
Standard Time. The workshop will be followed by one-on-one meetings
with company management teams at JMP Securities (450 Park
Avenue).
The workshop will address issues and opportunities in the
treatment of NASH, the current treatment paradigm, and clinical
issues including developments in diagnostics and clinical trial
design. The workshop includes a NASH primer led by Dr. Scott L.
Friedman, M.D., Dean for Therapeutic Discovery and Chief of the
Division of Liver Diseases, at the Icahn School of Medicine at
Mount Sinai.
About NASH
Non-alcoholic steatohepatitis (NASH), also known as fatty liver
disease, has become a common disease of the liver with the rise in
obesity rates, estimated to affect nine to 15 million people,
including children, in the U.S. Fatty liver disease is
characterized by the presence of fat in the liver along with
inflammation and damage in people who drink little or no alcohol.
Over time, patients with fatty liver disease can develop fibrosis,
or scarring of the liver, and it is estimated that as many as three
million individuals will develop cirrhosis, a severe liver disease
where liver transplantation is the only current treatment
available. Approximately 6,300 liver transplants are done on an
annual basis in the U.S. There are no drug therapies approved for
the treatment of liver fibrosis.
About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing
carbohydrate-based therapies for the treatment of fibrotic liver
disease and cancer based on the Company's unique understanding of
galectin proteins, key mediators of biologic function. We are
leveraging extensive scientific and development expertise as well
as established relationships with external sources to achieve cost
effective and efficient development. We are pursuing a clear
development pathway to clinical enhancement and commercialization
for our lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
CONTACT: Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2023 to Apr 2024